Yttrium-90
Updates to Article Attributes
Body
was changed:
Yttrium-90 (90Y) is a radioisotope; derives from the decay of 90Kr.
Yttrium-90 decays due to the emission of ß- particles, with a half-life of 2.67 days. It can be used for metabolic radiopharmaceutical therapy, for example: non-Hodgkin’s B-cell lymphomas radioimmunotherapy (radiopharmaceutical therapy and immunotherapy). The radiopharmaceutical used is 90Y-ibritumomab tiuxetan; it is a murine monoclonal antibody (mAb) directed at human CD20. Radio-yttrium is bound to the mAb through the tiuxetan chelator.
-<p>Yttrium-90 (<sup>90</sup>Y) is a radioisotope; derives from the decay of <sup>90</sup>Kr.</p><p>Yttrium-90 decays due to the emission of ß- particles, with a half-life of 2.67 days. It can be used for metabolic radiopharmaceutical therapy, for example: non-Hodgkin’s B-cell lymphomas radioimmunotherapy (radiopharmaceutical therapy and immunotherapy). The radiopharmaceutical used is <sup>90</sup>Y-ibritumomab tiuxetan; it is a murine monoclonal antibody (mAb) directed at human CD20.</p><p><!--[if gte mso 9]><xml>- +<p>Yttrium-90 (<sup>90</sup>Y) is a radioisotope; derives from the decay of <sup>90</sup>Kr.</p><p>Yttrium-90 decays due to the emission of ß- particles, with a half-life of 2.67 days. It can be used for metabolic radiopharmaceutical therapy, for example: non-Hodgkin’s B-cell lymphomas radioimmunotherapy (radiopharmaceutical therapy and immunotherapy). The radiopharmaceutical used is <sup>90</sup>Y-ibritumomab tiuxetan; it is a murine monoclonal antibody (mAb) directed at human CD20. Radio-yttrium is bound to the mAb through the tiuxetan chelator.</p><p><!--[if gte mso 9]><xml>
Unable to process the form. Check for errors and try again.